Safety Data from the VISION Trial

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Adding CAN-2409 to standard radiation therapy significantly improved disease-free survival and pathological complete response rates in intermediate-to-high-risk prostate cancer.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Olaparib and radium-223 bested radium-223 alone in radiographic progression-free survival in men with castration-resistant prostate cancer.

Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic castration-sensitive prostate cancer.